1. Thesis Chapters
1.1. Introduction
1.2. M&M
1.3. Aims
1.4. Results Chapter 1
1.4.1. The CD4 secretome
1.4.1.1. effect of Us2-11 immune evasion genes
1.4.1.2. Proteomics and pathway analysis
1.4.1.3. Array
1.4.2. IFN gamma from CD4 T cells what does it do
1.4.2.1. Is it antiviral
1.4.2.2. MHC Class II induction and immunology proteasome
1.4.3. MHC Class II and IFN gamma blocking experiments
1.4.4. Total PBMC
1.4.4.1. CD8
1.4.4.2. NK
1.4.4.3. Monocyte
1.4.4.4. CD4 cells
1.4.4.4.1. CD4 cells are anti-viral
1.4.5. Other cell types
1.4.5.1. epithelia RPE
1.4.5.1.1. Class II induction
1.4.5.1.2. CD4 Secretome induce
1.4.5.2. endothelial
1.4.5.2.1. CD4 Secretome induce
1.4.5.2.2. Class II induction
1.4.5.3. Monocyte
1.4.5.3.1. Macrophage
1.4.5.3.2. DCs
1.4.5.3.3. ? Use TB40e immunology virus
1.5. Results Chapter 2
1.5.1. Viral spread assay establishment
1.5.1.1. WT virus v delta Us2-11
1.5.1.2. PCR analysis of deletion
1.5.1.3. Functional analysis of deletion
1.5.2. anti viral control by CD4 T cells from Normal healthy
1.5.2.1. CD4 purification technique
1.5.2.1.1. Specific v non-specific activation
1.5.2.1.2. Direct CD4 v CD4 isolation
1.5.2.2. viral static v viracidal
1.5.3. VDA
1.5.3.1. CD4 cells with other cells
1.5.3.1.1. some CD8
1.5.3.1.2. NK
1.5.3.1.3. Monocytes
1.5.3.2. effect of Us2-11 immune evasion genes
1.6. Results Chapter 3
1.6.1. What T cells do this
1.6.1.1. CD107a or cytotoxicity readout?
1.6.1.2. VDA on sub T cell populations?
1.6.1.2.1. which ones?
1.6.1.2.2. CD4 RA
1.6.1.2.3. CD4 RO
1.6.1.2.4. CD4 CD28-
1.6.1.2.5. CD4 NKG2D
1.7. Results Chapter 4
1.7.1. CD4 cells in a clinical setting
1.7.1.1. CD4 T cell control by VDA
1.7.1.1.1. D+ R+
1.7.1.1.2. D+ R-